Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Maryann Cherubini"'
Autor:
Elizabeth Berry-Kravis, Randi Hagerman, Jeannie Visootsak, Dejan Budimirovic, Walter E. Kaufmann, Maryann Cherubini, Peter Zarevics, Karen Walton-Bowen, Paul Wang, Mark F. Bear, Randall L. Carpenter
Publikováno v:
Journal of Neurodevelopmental Disorders, Vol 9, Iss 1, Pp 1-18 (2017)
Abstract Background Arbaclofen improved multiple abnormal phenotypes in animal models of fragile X syndrome (FXS) and showed promising results in a phase 2 clinical study. The objective of the study is to determine safety and efficacy of arbaclofen f
Externí odkaz:
https://doaj.org/article/1600842ad64c4a2f93f317a6e4ba061b
Publikováno v:
Metabolites, Vol 2, Iss 3, Pp 596-613 (2012)
STX209 is an exploratory drug comprising the single, active R-enantiomer of baclofen which is in later stage clinical trials for the treatment of fragile x syndrome (FXS) and autism spectrum disorders (ASD). New clinical data in this article on the m
Externí odkaz:
https://doaj.org/article/0ea99961978841f1905a8d77cf6536eb
Autor:
Maryann Cherubini, Karen Walton-Bowen, Randi J Hagerman, Peter Zarevics, Walter E. Kaufmann, Elizabeth Berry-Kravis, Jeannie Visootsak, Dejan B. Budimirovic, Mark F. Bear, Paul Wang, Randall L. Carpenter
Publikováno v:
Journal of neurodevelopmental disorders, vol 9, iss 1
Journal of Neurodevelopmental Disorders
BioMedCentral
Journal of Neurodevelopmental Disorders, Vol 9, Iss 1, Pp 1-18 (2017)
Journal of Neurodevelopmental Disorders
BioMedCentral
Journal of Neurodevelopmental Disorders, Vol 9, Iss 1, Pp 1-18 (2017)
Background: Arbaclofen improved multiple abnormal phenotypes in animal models of fragile X syndrome (FXS) and showed promising results in a phase 2 clinical study. The objective of the study is to determine safety and efficacy of arbaclofen for socia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::133f24559988a642d80bb3814191c8cf
https://escholarship.org/uc/item/1w01b91f
https://escholarship.org/uc/item/1w01b91f
Autor:
Randall L. Carpenter, Paul P. Wang, Peter Zarevics, Maryann Cherubini, Edwin H. Cook, Jeremy Veenstra-VanderWeele, Mark F. Bear, Bryan H. King, Karen Walton-Bowen
Publikováno v:
PMC
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, vol 42, iss 7
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, vol 42, iss 7
Several lines of emerging data point to an imbalance between neuronal excitation and inhibition in at least a subgroup of individuals with autism spectrum disorder (ASD), including in those with fragile X syndrome (FXS), one of the most common geneti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cd3a0370e453eb6bcda30d30f75406f
https://hdl.handle.net/1721.1/126510
https://hdl.handle.net/1721.1/126510
Publikováno v:
Metabolites; Volume 2; Issue 3; Pages: 596-613
Metabolites, Vol 2, Iss 3, Pp 596-613 (2012)
Metabolites
Metabolites, Vol 2, Iss 3, Pp 596-613 (2012)
Metabolites
STX209 is an exploratory drug comprising the single, active R-enantiomer of baclofen which is in later stage clinical trials for the treatment of fragile x syndrome (FXS) and autism spectrum disorders (ASD). New clinical data in this article on the m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37e676b327833c5e77e399f6737c3d7a
https://doi.org/10.3390/metabo2030596
https://doi.org/10.3390/metabo2030596
Autor:
Maryann Cherubini, David Jackson, Daniel T. Kennedy, William K. Schmidt, Bruce Wallin, Roger A. Donovick, Daniel M. Paulson, Wei Du, Lee Techner, Randall L. Carpenter, Yuju Ma
Publikováno v:
The Journal of Pain. 6:184-192
Alvimopan has been shown to reverse the inhibitory effect of opioids on gastrointestinal transit without affecting analgesia. We evaluated oral alvimopan, 0.5 or 1 mg, versus placebo, once daily for 21 days, in 168 patients with opioid-induced bowel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::476c7fe4946ad689cbf8d68516344ce9
https://doi.org/10.1016/j.jpain.2004.12.001
https://doi.org/10.1016/j.jpain.2004.12.001
Autor:
Danh V. Nguyen, Elizabeth Berry-Kravis, Randall L. Carpenter, Yi Mu, David R Hessl, Peter Zarevics, Joseph Gonzalez-Heydrich, Randi J Hagerman, Mark F. Bear, Karen Walton-Bowen, Maryann Cherubini, Paul P. Wang, Barbara Rathmell
Publikováno v:
Bear via Courtney Crummett
Research on animal models of fragile X syndrome suggests that STX209, a γ-aminobutyric acid type B (GABA[subscript B]) agonist, might improve neurobehavioral function in affected patients. We evaluated whether STX209 improves behavioral symptoms of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e38e8c80bc651cad7b0b9856399d15a2
https://pubmed.ncbi.nlm.nih.gov/22993294
https://pubmed.ncbi.nlm.nih.gov/22993294
Autor:
Warren E. Enker, Bruce G. Wolff, Wei Du, Conor P. Delaney, John G. Fort, Kirk A. Ludwig, James Cucinotta, Lee Techner, Maryann Cherubini
Publikováno v:
Archives of Surgery. 143:1098
To investigate the efficacy and safety of alvimopan, 12 mg, administered orally 30 to 90 minutes preoperatively and twice daily postoperatively in conjunction with a standardized accelerated postoperative care pathway for managing postoperative ileus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7494ecd3d619914e13a5ce886aad6ec
https://doi.org/10.1001/archsurg.143.11.1098
https://doi.org/10.1001/archsurg.143.11.1098